https://oncbrain.oncologytoolkit.com/ AI-summarized oncology meeting studies, curated by a subspecialist. One item per study. en Mon, 28 Sep 2026 00:00:00 GMT https://oncbrain.oncologytoolkit.com/2026-09-28/#swog-s1827-maverick https://oncbrain.oncologytoolkit.com/2026-09-28/#swog-s1827-maverick Mon, 28 Sep 2026 00:00:00 GMT thoracic [Challenges SOC] MRI surveillance alone beat MRI + PCI for cognitive failure-free survival, HR 0.60 (90% CI 0.46-0.78), in LS- and ES-SCLC without brain mets after first-line therapy. Eligible: LS- or ES-SCLC, no brain mets on MRI after 1st-line therapy https://oncbrain.oncologytoolkit.com/2026-09-28/#pace-a https://oncbrain.oncologytoolkit.com/2026-09-28/#pace-a Mon, 28 Sep 2026 00:00:00 GMT prostate [Caveats dominate] ≥1 urinary pad 14/29 (48%) RP vs 3/36 (8%) SBRT; BCF HR 0.48 (95% CI 0.16-1.46), mFU 8 yrs, GG1-2 localised PCa. Eligible: Localised low/intermediate-risk PCa (GG1-2), surgical candidates, no ADT https://oncbrain.oncologytoolkit.com/2026-09-28/#stop-iadt-sbrt https://oncbrain.oncologytoolkit.com/2026-09-28/#stop-iadt-sbrt Mon, 28 Sep 2026 00:00:00 GMT prostate [Early signal] 3-yr biochemical progression 21% vs 60% (p=0.004) adding SBRT to intermittent ADT in PSMA PET-detected, conventional-imaging-negative oligometastatic HSPC/BCR. Eligible: PSMA PET ≤3 mets, CI-negative BCR or de novo oligometastatic HSPC https://oncbrain.oncologytoolkit.com/2026-09-28/#roads https://oncbrain.oncologytoolkit.com/2026-09-28/#roads Mon, 28 Sep 2026 00:00:00 GMT cns [Challenges SOC] Cs-131 tile brachytherapy at resection cut surgical bed recurrence vs post-op SRT: time-to-SBR HR 0.06 (0.01-0.46), SB-RFS HR 0.48, in newly diagnosed resected brain mets. Eligible: Newly diagnosed brain met 2-7 cm indicated for resection